These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 25369769)

  • 1. Traceability of biologicals: present challenges in pharmacovigilance.
    Vermeer NS; Spierings I; Mantel-Teeuwisse AK; Straus SM; Giezen TJ; Leufkens HG; Egberts TC; De Bruin ML
    Expert Opin Drug Saf; 2015 Jan; 14(1):63-72. PubMed ID: 25369769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports.
    Klein K; Scholl JH; Vermeer NS; Broekmans AW; Van Puijenbroek EP; De Bruin ML; Stolk P
    Drug Saf; 2016 Feb; 39(2):185-92. PubMed ID: 26719190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The UK BIO-TRAC Study: A Cross-Sectional Study of Product and Batch Traceability for Biologics in Clinical Practice and Electronic Adverse Drug Reaction Reporting in the UK.
    Klein K; Hazell L; Stolk P; Shakir S
    Drug Saf; 2020 Mar; 43(3):255-263. PubMed ID: 31872358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifiability of Biologicals in Adverse Drug Reaction Reports Received From European Clinical Practice.
    Vermeer NS; Giezen TJ; Zastavnik S; Wolff-Holz E; Hidalgo-Simon A
    Clin Pharmacol Ther; 2019 Apr; 105(4):962-969. PubMed ID: 30460997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current state of biologic pharmacovigilance in the European Union: improvements are needed.
    Felix T; Jordan JB; Akers C; Patel B; Drago D
    Expert Opin Drug Saf; 2019 Mar; 18(3):231-240. PubMed ID: 30714424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biologicals and Biosimilars: Gaps in the Pharmacovigilance System in Portugal].
    Portela MC; Sinogas C; Almeida FA; Baptista-Leite R; Castro-Caldas A
    Acta Med Port; 2017 Mar; 30(3):205-212. PubMed ID: 28550830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knowledge of Adverse Drug Reaction Reporting and the Pharmacovigilance of Biological Medicines: A Survey of Healthcare Professionals in Ireland.
    O'Callaghan J; Griffin BT; Morris JM; Bermingham M
    BioDrugs; 2018 Jun; 32(3):267-280. PubMed ID: 29721705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacovigilance and biosimilars: considerations, needs and challenges.
    Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
    Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of exposure misclassification in spontaneous ADR reports on the time to detection of product-specific risks for biologicals: a simulation study.
    Vermeer NS; Ebbers HC; Straus SM; Leufkens HG; Egberts TC; De Bruin ML
    Pharmacoepidemiol Drug Saf; 2016 Mar; 25(3):297-306. PubMed ID: 26676881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologicals and biosimilars: safety issues in Europe.
    Portela MDCC; Sinogas C; Albuquerque de Almeida F; Baptista-Leite R; Castro-Caldas A
    Expert Opin Biol Ther; 2017 Jul; 17(7):871-877. PubMed ID: 28540760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilars: pharmacovigilance and risk management.
    Zuñiga L; Calvo B
    Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):661-9. PubMed ID: 20583204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges and Opportunities for the Traceability of (Biological) Medicinal Products.
    Klein K; Stolk P
    Drug Saf; 2018 Oct; 41(10):911-918. PubMed ID: 29721822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Traceability of biopharmaceuticals in spontaneous reporting systems: a cross-sectional study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance databases.
    Vermeer NS; Straus SM; Mantel-Teeuwisse AK; Domergue F; Egberts TC; Leufkens HG; De Bruin ML
    Drug Saf; 2013 Aug; 36(8):617-25. PubMed ID: 23771794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacovigilance of Biologics in a Multisource Environment.
    Sagi S; Cohen HP; Woollett GR
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1249-1254. PubMed ID: 29172979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is pharmacovigilance of biologicals cost-effective?
    Claus B
    Int J Clin Pharm; 2018 Aug; 40(4):787-789. PubMed ID: 30051230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacovigilance Considerations for Biosimilars in the USA.
    Grampp G; Felix T
    BioDrugs; 2015 Oct; 29(5):309-21. PubMed ID: 26419971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies.
    Francescon S; Fornasier G; Baldo P
    Int J Clin Pharm; 2018 Aug; 40(4):778-782. PubMed ID: 30094558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drift, evolution, and divergence in biologics and biosimilars manufacturing.
    Ramanan S; Grampp G
    BioDrugs; 2014 Aug; 28(4):363-72. PubMed ID: 24567263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacovigilance of biopharmaceuticals: challenges remain.
    Giezen TJ; Mantel-Teeuwisse AK; Leufkens HG
    Drug Saf; 2009; 32(10):811-7. PubMed ID: 19722725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nomenclature and traceability debate for biosimilars: small-molecule surrogates lend support for distinguishable nonproprietary names.
    Chao J; Skup M; Alexander E; Tundia N; Macaulay D; Wu E; Mulani P
    Adv Ther; 2015 Mar; 32(3):270-83. PubMed ID: 25772256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.